Rhodiola rosea is an herb purported to possess adaptogenic and ergogenic properties and has recently been the subject of increased interest. The purpose of this article was to review and summarize recent investigations of the potential performance-enhancing properties of Rhodiola rosea. Such studies have generated equivocal results. Several investigations conducted in Eastern Europe have indicated that Rhodiola rosea ingestion may produce such positive effects as improved cognitive function and reduced mental fatigue. Other research from this region has illustrated enhanced endurance exercise performance in both humans and rats. Studies conducted in Western Europe and in North America have indicated that Rhodiola rosea may possess substantial antioxidant properties but have produced mixed results when attempting to demonstrate an ergogenic effect during exercise in humans.
Several herbal supplements have been purported to possess ergogenic effects, including ginseng, yohimbe, cordyceps sinensis, and others. In addition to potential specific ergogenic effects, such herbs are often marketed to the general public as adaptogens. An adaptogen is a substance that allows an organism to counteract adverse physical, chemical, or biological stressors by generating non-specific resistance.
One herb purported to possess adaptogenic and ergogenic properties and that has been the subject of increased recent interest is Rhodiola rosea. Rhodiola rosea (Crassulaceae family) is an herb that grows in the mountainous and arctic regions of North America, Europe, and Asia (5) . Also known as arctic root, rose root, and golden root, Rhodiola rosea has been used in folk medicine to treat fatigue and other maladies in Eastern Europe, Scandinavia, and Asia for centuries (5, 9) . In the US, it is marketed as a powerful adaptogen and is sold at virtually every nutrition outlet. The Natural Medicines Comprehensive Database lists Rhodiola rosea as "possibly safe" with no reported adverse reactions. Despite its history and popularity, contemporary studies that have investigated the effectiveness of Rhodiola rosea in performance enhancement have produced mixed results.
There are over 200 species of Rhodiola (16) , each with distinctive pharmacology. The phenylethanol salidroside is common throughout the genus. Rhodiola rosea is distinguished from other species of Rhodiola by the presence of three watersoluble cinnamyl glycosides: rosavin, rosin, and rosarin, which are collectively known as rosavins. (See Figures 1 through 3) The presence of these glycosides is presumed to give Rhodiola rosea its adaptogenic characteristics (2) . Rhodiola rosea has been by far the species most intensively studied, particularly in humans, and is the only Rhodiola species considered safe for human consumption (5) .
Nearly all of the early research of Rhodiola rosea's pharmacological qualities was conducted and published in Russia and Bulgaria. Readers may refer to a review by Brown et al. (5) for a detailed history of Rhodiola rosea pharmacology dating as far back as the 18th century. This article, while recognizing the importance of such study, will focus primarily on recent investigations of the potential performanceenhancing properties of Rhodiola rosea. While those investigations have produced mixed results, several have indicated that Rhodiola rosea ingestion may produce such positive effects as improved cognitive function (28) , reduced mental fatigue (9, 27) , anti-adrenergic resistance to stress-induced arrythmias (20, 21) , free radical mitigation (12, 31) , and enhanced endurance performance (2, 11, 28 .) Potential mechanisms for these purported effects have yet to be fully described. Figure 4 presents the currently theorized actions and mechanisms. 
Effects on Cognitive and Neural Function
In a seminal study, Petkov et al. (24) found that following a single dose (ingested per os) of 0.10 mg Rhodiola rosea extract, rats improved learning by up to 30% compared with control rats as measured by using a maze method with both negative (electric shock) and positive (food) reinforcement. They also saw significant improvement of the long-term memory after a 10-d treatment with the same dose of the extract. However, in the two other doses tested (0.02 mg and 1.0 mg per rat), rats failed to display the same improvements, although rats administered the 0.02 mg dose did show a trend towards improvement when compared with controls. Also, during some other common tests of learning and memory, such as "step-down" and "step-through" passive avoidance of electroshock, Rhodiola extract in all the doses used (0.02, 0.10, and 1.0 mg per rat) had no substantial effect on learning and/or memory. Petkov et al. attributed the differences in results of the various tests to the potential differences in various neurotransmitter levels when performing different tasks but they did not examine such levels. In a similar study, Lazarova et al. (18) failed to observe any effect of Rhodiola rosea extract, administered orally in a dose of 0.10 mg per rat for 10 d, on the memory-impairing action of electroshock. Spurred by such mixed results, researchers have continued to explore Rhodiola rosea's potential effect on cognition.
Spasov et al. (28) investigated the effect of Rhodiola rosea extract (SHR-5) in 40 male Indian medical students studying in Russia during a stressful examination period. SHR-5 is a commonly used, specialized extract of Rhodiola rosea commercially produced in Sweden (Swedish Herbal Institute, Göteborg, Sweden). The students ingested either 100 mg/d of SHR-5 or a placebo for 20 d preceding and during an examination period. Physical and mental performance was assessed before and after the period through a series of objective tests and subjective questionnaires. They observed a treatment group improvement in a motor skill test wherein the subjects moved an object through a maze as fast as possible while trying not to touch the walls of the maze. Students in the treatment group also scored higher on their academic exams than those in the placebo group. Subjectively, SHR-5 treated subjects reported less mental fatigue and a greater sense of well-being. However, the investigators found no differences between groups in a text-correction mental function test or in a neuro-motor speed test in which the students were asked to tap a button as often as possible in 30 s.
Darbinyan et al. (9) measured the effect of daily Rhodiola rosea ingestion (170 mg/d) on fatigue during night duty among a group of 56 young, healthy physicians. The effect was measured by a series of trials testing associative thinking, short-term memory, calculation, concentration, and speed of audio-visual perception that they incorporated into a "Fatigue Index." These parameters were tested before and after night duty during three periods of 2 wk each: a) a test period of 170 mg Rhodiola rosea/placebo tablet daily, b) a washout period, and c) a third period of 170 mg Rhodiola rosea/placebo daily, in a double-blind cross-over trial. A significant improvement in their Fatigue Index was observed in the treatment group during the first 2 wk period. However, the improvement was not observed during the third period. The authors theorized that an acute change in their subjects' duty schedules prior to the third testing session was responsible for the lack of observed effect.
Shevtsov et al. (27) recently completed a study similar to that of Darbinyan et al. in their examination of the effects of standardized Rhodiola rosea extract on capacity for mental work during a period of fatigue and stress as measured by a fatigue index that incorporated both objective tests of cognitive function and subjective assessments of well-being. Their subjects were also young males undergoing a period of fatigue and stress. However, in this study, Shevtsov et al. investigated the effect of a single dose of either 370 mg or 555 mg. They showed a pronounced (13 to 15%) anti-fatigue effect reflected in the fatigue index in both treatment groups. Results of the two treatment groups were not significantly different from each other but were significantly better than those for both the placebo and control groups.
In contrast to the apparent promise of Rhodiola rosea to enhance cognitive performance and reduce fatigue in the above studies, De Bock et al. (11) found no effect of acute or chronic ingestion of a 200 mg Rhodiola rosea extract on a variety of neural and cognitive tests in healthy, young males and females. The tests included speed of limb movement, aural and visual reaction time, and the ability to sustain attention. The results of De Bock's study may be given more weight than many of the above studies (9, 18, 24) as the methods and results appear more clear and interpretable.
Few of the aforementioned studies tested or even hypothesized as to the mechanism by which Rhodiola rosea ingestion may have improved cognitive and/or neural performance. Rhodiola rosea was originally believed to be a CNS stimulant (5, 23.) Previous reviews (5, 16) and manuscripts (18, 24) have claimed (or at least propagated the idea) that Rhodiola rosea may increase serotonin levels in the frontal cerebral cortex of rats while decreasing serotonin in the hypothalamus. However, the only published data we could find that provided direct evidence of such effects is that of Stancheva et al. (29) , a study in which the methods and conclusions seem incomplete. If Rhodiola rosea does influence serotonin levels in such a manner, that could provide a mechanism by which fatigue and/or cognitive performance is affected. Although the exact role of serotonergic neurotransmission in the frontal cerebral cortex remains largely unknown, it has been implicated in the control of numerous behavioral and physiological functions. In recent reviews, both Buhot et al. (6) and Meeter et al. (23) outlined the importance of adequate serotonin transmission in learning and memory performance. Specifically, Buhot et al. (6) cites several investigations that have demonstrated that the loss of serotonergic transmission induces persistent memory impairments in rats. If so, perhaps increased serotonergic transmission could improve memory. However, increased brain serotonin levels have been correlated with increased central fatigue (7, 26) . Such an effect would be contrary to results of several of the above studies (9, 27, 28) that reported reduced levels of fatigue in human subjects who had ingested Rhodiola rosea.
Several Russian studies have presented evidence that Rhodiola rosea may facilitate transport of neurotransmitters within the brain (5, 15, 19) . Additionally, Rhodiola rosea has been shown (19, 29) to stimulate the synthesis, transport, and receptor activity of monoamines and opioid receptors and peptides such as β-endorphins. It has been suggested that an increase in levels of some brain neurotransmitters such as β-endorphins could lead to an improvement in cognitive performance (4.) Based on the mixed results of these studies (see Table 1 for a summary), it is impossible to determine with certainty whether Rhodiola rosea ingestion improves neural and/or cognitive performance. It appears that it may have some effect. However, that effect seems to be mediated by dosage and test/task specificity. Moreover, the mechanism(s) of the effect have yet to be clearly defined.
Effect on Physical Performance
Rhodiola rosea is often prescribed in Sweden and Russia for the purpose of increasing work capacity (5, 9) . Nonetheless, like those that have explored the potential cognitive benefits of Rhodiola rosea ingestion, well-controlled studies of Rhodiola rosea's effect on physical performance have been equivocal (Table 2) . Research from Russia in the 1960s and 1970s indicated an ergogenic effect of Rhodiola rosea in trained athletes and healthy adults (5). However, much of this early research was performed as Russian student dissertations, which have not been translated or published, rendering it difficult to evaluate the quality of their methods and analyses. Again, Brown (5) has provided a thorough description of the early research.
More recently, Spasov et al. (28) in their study of Indian medical students mentioned above, found a trend (P ~ 0.1) towards an increase in work capacity for the treatment group during a PWC-170 ergometry test. That test was based on work capacity at a continuous HR of 170 bpm. The Rhodiola rosea group was able to achieve 980 ± 40 kgm/min versus the 920 ± 52 kgm/min of the placebo group. Although a trend towards a placebo effect was observed (both groups produced approximately 810 kgm/min before treatment) the change in work capacity between pre-and post-treatment was significantly different between groups. In addition, the investigators observed a significantly faster decrease in heart rate following the test in the Rhodiola rosea group than in the placebo group. This kind of recovery difference is normally seen in endurance trained versus untrained groups although the potential intrinsic, neural, and/or hormonal actions responsible for the difference are still unclear (10). DeBock et al. (11) tested the effect of a single or 4-wk dose of 200 mg/d of Rhodiola rosea on endurance capacity and strength, in addition to the cognitive parameters mentioned earlier, in a crossover design. They found a significantly higher time-to-exhaustion (17.2 ± 0.8 vs. 16.8 ± 0.7 min) and VO 2peak (52.9 ± 2.7 vs. 50.9 ± 1.8 mL · kg · min) in subjects who had received a single 200 mg dose. VO 2peak values following 4 wk of Rhodiola rosea ingestion were not significantly different between groups. Maximal isometric knee-extension values were not different between treatment groups during the acute or the chronic ingestion trials. DeBock et al. speculated that the difference in time-to-exhaustion and VO 2peak in the acute trial was due to a stimulation of β-endorphin synthesis, transport, or receptor activity. Specifically, they hypothesized that because high intensity exercise is associated with discomfort and pain and β-endorphins are associated with effecting pain tolerance, their subjects may have been able to tolerate a higher intensity of exercise due to higher b-endorphin activity. However, they did not assay plasma β-endorphins nor did they measure RPE during their VO 2peak test. Further, Grossman and Sutton (14) contend that β-endorphins partially inhibit the ventilatory response to exercise, making it unlikely that increased β-endorphin activity was responsible for the increased VO 2peak observed by DeBock et al.
Abidov et al. (2) have proposed a different mechanism by which Rhodiola rosea ingestion could enhance exercise performance. They found that rats treated with Rhodiola rosea extract (50 mg · kg · d) significantly (by 24.6%) had a longer duration of exhaustive swimming in comparison with control rats. In their search for a potential mechanism, they measured ATP content in isolated rat muscle mitochondria by the bioluminescence method before and after six consecutive days of exhaustive swimming. They observed that ATP content decreased significantly less in the treatment rats than in the controls both immediately after swimming on the sixth day (ATP was 4.85 ± 0.30 µmol/g in the treated rats versus 3.86 ± 0.40 in the controls) and after an additional 24-h rest period (5.22 ± 0.40 vs. 4.69 ± 0.50). They concluded that Rhodiola rosea extract activated the synthesis or resynthesis of ATP in mitochondria and stimulated restorative energy processes after intense exercise.
That investigation was followed with another in which this same group of researchers examined effects of extracts of Rhodiola rosea on blood levels of inflammatory C-reactive protein (C-rp) and creatinine kinase (CK) in healthy untrained volunteers before and after exhausting exercise (1). C-rp and CK are markers of inflammation and muscle damage, and are normally elevated after exercise in proportion to the amount of activity and muscle injury (15, 17, 30) . Subjects receiving 680 mg RHODAX TM (60 mg Rhodiola rosea extract) daily for 30 d prior to and 6 d after exhaustive cycling exercise displayed lower C-rp and CK values than those who received a placebo and controls who did not ingest anything. Although they did not report any exercise performance measures, these findings indicate that Rhodiola rosea ingestion may mimic adaptations that can occur through long-term endurance training. Mattusch et al. (22) showed that post-exercise C-rp levels fell after 9 months of running training despite an increased workload while Lakka et al. (17) found a similar response in C-rp levels after 20 wk of training. Kasapis and Thompson (15) recently provided an outstanding review of how exercise affects serum CRP and CK levels.
Studies by De Sanctis et al. (12) , Boon-Niermeijer et al., (3) and Wing et al. (31) have further explored the potential free radical mitigation of Rhodiola rosea seen by Abidov. De Sanctis et al. introduced hypochlorous acid (a powerful oxidant) to in vitro human red blood cells that had been incubated with R. rosea extract (150 µl/100 µl packed RBC). They found that Rhodiola rosea protected, in a dose-dependent manner, human erythrocytes from the glutathione depletion, glyceraldehyde-3-phosphate dehydrogenase inactivation, and hemolysis induced by the oxidant. Wing et al. (31) gave 15 subjects 1788 mg of Rhodiola rosea or placebo for 7 d while they underwent repeated normobaric hypoxia exposures. Although blood oxygen levels were not affected by Rhodiola rosea ingestion, lipid peroxides decreased, indicating the potential of Rhodiola rosea to decrease free radical formation caused by hypoxia. Boon-Niermeijer et al. (3) demonstrated a significant protective effect of Rhodiola rosea on snail larvae exposed to environmental stressors, including the superoxide radical-inducing agent menadione. The antioxidant characteristics reported by these investigators could be a mechanism by which Rhodiola rosea improves performance. Growing evidence indicates that reactive oxygen species are responsible for exercise-induced protein oxidation and contribute to muscle fatigue (25) . However, studies that have attempted to improve physical performance through antioxidant supplementation have been equivocal at best (25) , with more success in animals than in humans. (13) found no effect of a commercial herbal-based formula called Optygen TM (First Endurance, Salt Lake City, UT) in 17 competitive amateur cyclists. Optygen TM lists Rhodiola rosea and Cordyceps sinensis (another herb that has been shown in some studies to increase VO 2peak ) as its primary ingredients, along with a "proprietary blend of other nutrients." The treatment group ingested six capsules per day (a total of 2 g of Cordyceps sinensis, 600 mg of Rhodiola rosea) for the first 4 d followed by three capsules per day for 11 d per the manufacturer's recommendations while the placebo group ingested an equivalent placebo. The authors found no differences in VO 2peak , peak heart rate, peak power output, lactate threshold, or ventilation threshold (VT) between or within groups at any time. A similar study by Colson et al. (8) found no differences in muscle tissue oxygen saturation, VO 2max , VT, or time to exhaustion between or within a group of male cyclists who took Optygen TM for 13 d versus a placebo group.
Based on the collective results of these studies, it remains unclear as to whether Rhodiola rosea possesses some ability to enhance exercise performance. Additionally, the specific circumstances, e.g., dosage, population, exercise mode, under which it may work are still ambiguous although it seems that endurance exercise performance is more likely to be influenced by Rhodiola rosea ingestion than is strength. The means by which it may exert its ergogenic effect(s) also remains ambiguous. Given current evidence, we believe enhanced mitochondrial function (2) and/or free radical mitigation (3, 12, 31) are the most plausible mechanisms by which Rhodiola rosea may improve physical performance. Additional, more tightly controlled studies with human subjects are needed to determine if such effects truly exist.
